BOLA FADIPE: Open Payments
NPI 1477981496 · UNION, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,058 in 32 payments from 9 companies in 2025. Trend: 2023 $441 · 2024 $926 · 2025 $1,058
Food & beverage: $1,058
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $390 |
| E.R. Squibb & Sons, L.L.C. | 7 | $216 |
| Supernus Pharmaceuticals, Inc. | 2 | $139 |
| Otsuka America Pharmaceutical, Inc. | 2 | $138 |
| Alkermes, Inc. | 1 | $76 |
| Bausch Health US, LLC | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
Products named: VRAYLAR, COBENFY, Qelbree, ABILIFY MAINTENA, LYBALVI, APLENZIN, FANAPT, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
